Does Ketamine Show Up on a Drug Test?

If you are receiving ketamine therapy — or thinking about starting — and you are subject to drug testing at work, through the courts, or as part of another program, the question is straightforward: will it show up?

The short answer is no, not on the tests most people encounter. Standard workplace drug panels do not screen for ketamine. But the longer answer matters too, because specialized tests can detect it, and patients in legitimate treatment should understand how the system works and what to do if the question ever comes up.

Standard drug tests do not include ketamine

The drug test used by most U.S. employers is based on the federal SAMHSA-5 panel, which screens for five substances: marijuana, cocaine, amphetamines, opiates, and phencyclidine (PCP). Ketamine is not one of them.

Extended panels — the 10-panel and 12-panel tests that some employers and programs use — add substances like benzodiazepines, barbiturates, and methadone. But even these expanded screens typically do not include ketamine. There is no single universal definition of what a "10-panel" or "12-panel" test covers. The exact contents vary by laboratory and whoever ordered the test. In nearly all cases, ketamine is not a default analyte on any of them.

For ketamine to appear on a drug test result, it has to be specifically ordered as a separate test or add-on. That does not happen in routine employment screening.

When ketamine testing is specifically ordered

There are situations where a test panel does include ketamine, and patients should be aware of them:

• Post-incident workplace testing. After an accident or safety event, an employer may order expanded testing beyond the standard panel.
• Pain management clinics. Clinics that prescribe ketamine or monitor patients for substance use sometimes include it in their panels.
• Probation, parole, or court-ordered testing. Standard panels here are usually 5- or 10-panel, but supervising officers and courts can customize the panel based on an individual's history.
• Forensic or legal investigations. Drug-facilitated assault cases, impaired driving investigations, or custody disputes may involve targeted ketamine testing.
• DOT-regulated employers. The Department of Transportation mandates only the SAMHSA-5 panel. DOT employers cannot add ketamine to a DOT test — but they can commission a separate, non-DOT test if they want to screen for it.

If you work in a role with specialized testing protocols, or if you are on supervised release of any kind, do not assume you know what your panel covers. Ask.

Detection windows by test type

If ketamine is specifically tested for, how long it remains detectable depends on the type of test. These are estimates — individual results vary based on dose, frequency, metabolism, body composition, liver and kidney function, and the sensitivity of the test itself.

Urine is the most common method. After a standard therapeutic dose, ketamine's primary metabolites — norketamine and dehydronorketamine — are typically detectable for about 3 to 14 days. Urine tests detect metabolites rather than the drug itself, which is why the detection window extends well beyond the period when you actually feel any effects.

Blood tests have a narrow window and are used mainly in emergency or legal contexts where recent use is the relevant question.

Saliva tests are non-invasive and sometimes used for on-site screening. They may have lower sensitivity for ketamine compared to urine or blood.

Hair follicle tests have the longest window. Each centimeter of hair represents roughly one month of growth. Published case reports have found ketamine detectable in hair 17 weeks after just three therapeutic IV doses. Hair testing is uncommon in routine employment screening due to cost and complexity, and cutoff levels for ketamine in hair are not standardized across laboratories.

What does ketamine show up as on a drug test?

On a test that specifically screens for it, ketamine is reported as ketamine or its metabolites. It does not show up as another substance.

Ketamine does not cause a false positive for PCP. This is a common concern because ketamine is chemically related to phencyclidine, but research confirms that pharmaceutical ketamine at therapeutic concentrations does not cross-react with PCP immunoassays. The false-positive issue applies to certain novel designer analogues — recreational street drugs — not to the pharmaceutical ketamine used in medical treatment.

There is a separate false-positive concern worth knowing about: quetiapine (Seroquel), a commonly prescribed antipsychotic, has been documented to cause false positive results on ketamine-specific immunoassay screens. Dextromethorphan, found in over-the-counter cough medications, has also been reported to cause cross-reactivity. In either case, confirmatory testing using mass spectrometry can definitively resolve any ambiguous result.

Factors that affect how long ketamine stays in your system

Several variables influence how quickly your body clears ketamine:

Dose and frequency. Higher doses and repeated use extend the detection window. A single therapeutic infusion clears faster than a series of treatments given over several weeks.

Route of administration. Bioavailability varies significantly — near 100 percent for IV, roughly 93 percent for IM, 45 to 50 percent for intranasal (including Spravato), and 16 to 29 percent for oral. More drug reaching the bloodstream means potentially longer detection.

Liver function. Ketamine is metabolized in the liver by cytochrome P450 enzymes. Genetic variations in these enzymes can substantially affect clearance rates. Liver impairment slows metabolism further.

Kidney function. About 90 percent of ketamine is excreted in urine as metabolites. Reduced kidney function can slow elimination.

Body composition. Ketamine is highly fat-soluble. It can accumulate in fatty tissue and be released more slowly, which may extend detection in some individuals.

Drug interactions. CYP3A4 inhibitors — such as clarithromycin — can raise ketamine concentrations. Enzyme inducers like rifampicin can accelerate clearance. If you are on multiple medications, mention this to your ketamine provider.

Test sensitivity. Different laboratories use different cutoff concentrations. A sample below the lab's cutoff registers as negative even if trace amounts are present.

Detection is not impairment

This distinction matters. Ketamine's dissociative effects resolve within a few hours of a therapeutic session. But metabolites can remain detectable in urine for one to two weeks after those effects have completely worn off. A positive urine test for ketamine does not mean the person was impaired at the time the sample was collected — or at any recent point. It means metabolites were present.

What patients in treatment should know

If you are receiving legally prescribed ketamine therapy — whether IV infusions, IM injections, or FDA-approved esketamine (Spravato) nasal spray — you have meaningful protections if a drug test ever specifically detects ketamine.

The Medical Review Officer process. In federally mandated testing programs and many private-sector programs, a non-negative lab result does not go directly to your employer. It goes to a Medical Review Officer — a licensed physician whose job is to determine whether there is a legitimate medical explanation. The MRO contacts you privately, reviews your prescription documentation, and may verify directly with your prescribing physician or pharmacy. If your use is confirmed as legitimate and prescribed, the MRO typically reports the result to your employer as negative. The employer generally does not learn which medication you take, your diagnosis, or your treatment details.

The ADA provides additional protection. The Americans with Disabilities Act protects employees using lawfully prescribed medications for covered health conditions. Treatment-resistant depression and other conditions treated with ketamine are often considered covered disabilities when they substantially limit major life activities.

Esketamine and ketamine are both detectable. Spravato is the S-enantiomer of ketamine and will be detected by any test that detects ketamine. The same detection windows and protections apply.

What to do if you are concerned

Keep your documentation accessible. Have a copy of your prescription or treatment authorization, your prescriber's contact information, your clinic name, and your treatment dates. You do not need to disclose any of this to your employer — it is for the MRO if the situation ever arises.

Ask your provider. If you are in a safety-sensitive role, subject to random testing, or on any form of supervised release, talk to your treatment provider about what your specific testing situation involves and what documentation they can provide.

If you are on probation or parole, talk to your supervising officer before starting treatment. Probation panels can be customized, and beginning ketamine therapy without disclosure could create problems that proactive communication would have prevented.

Do not withhold medical information from an MRO. The MRO process exists specifically to protect patients using prescribed medications. Cooperating with it is how you protect yourself.

Common misconceptions

"Ketamine will show up on any drug test." It will not. Standard 5-panel and 10-panel tests do not include it. Only a separately ordered, specialized test would detect it.

"Ketamine shows up as PCP." Pharmaceutical ketamine at therapeutic doses does not cross-react with PCP immunoassays. This confusion likely stems from their chemical relationship, but the drugs behave differently in testing.

"There is nothing I can do if I test positive." If you are receiving prescribed ketamine therapy, the MRO process exists precisely for this situation. Proactive documentation and cooperation protect you.

"A few infusions will not leave traces for long." Even a small number of therapeutic IV doses have been detected in hair months later. Detection windows — particularly for hair — can outlast the treatment period itself.

Frequently asked questions

Does ketamine show up on a standard drug test? No. Standard 5-panel and 10-panel employment drug tests do not screen for ketamine. It requires a separately ordered, specialized test.

How long does ketamine stay in urine? After a standard therapeutic dose, ketamine metabolites are typically detectable in urine for approximately 3 to 14 days. With heavier or repeated use, detection may extend to around 30 days. Individual metabolism varies.

What does ketamine show up as on a drug test? On a test specifically screening for it, ketamine is reported as ketamine or its metabolites. It does not cause a false positive for PCP at therapeutic concentrations.

Will my employer find out about my ketamine treatment? In most cases, no. Standard tests do not screen for it. If an expanded test were ordered and came back non-negative, the MRO process allows you to verify your prescription privately. The employer typically receives only a negative or positive result, not medication details.

Does Spravato show up differently than IV ketamine? No. Spravato (esketamine) is the S-enantiomer of ketamine and is detected by the same tests. The same detection windows and protections apply.

Should I tell my employer I am receiving ketamine therapy? You are not required to disclose your specific medications to your employer. If a drug test issue arises, the MRO is the appropriate person to share prescription information with — not your employer directly.

Finding a provider

If you are looking for a ketamine therapy provider, our directory lists clinics across the country. You can browse by location, clinic type, or treatment approach to find providers near you.

Related articles

• Ketamine Side Effects: What to Expect and When to Worry
• What Does Ketamine Therapy Feel Like?
• How Much Does Ketamine Therapy Cost?
• Does Insurance Cover Ketamine Therapy?

Sources

• SAMHSA. Workplace Drug Testing Resources. Updated July 2024.
• NIH/NCBI StatPearls. Ketamine — Pharmacology. Updated January 2024.
• Dinis-Oliveira, R.J. (2017). Metabolism and Metabolomics of Ketamine: A Toxicological Approach. Forensic Science Research. PMC.
• Skaugen, J.M. et al. (2019). Novel Ketamine Analogues Cause a False Positive Phencyclidine Immunoassay. Annals of Clinical Biochemistry. SAGE Journals.
• False Positive Ketamine Urine Immunoassay Screen Result Caused by Quetiapine. PubMed. 2017.
• Cut-off Proposal for the Detection of Ketamine in Hair. Forensic Science International. 2015.
• Duration of Ketamine Detection in Hair After Treatment Cessation. Drug Testing and Analysis. 2023. PubMed.
• U.S. Department of Transportation. Back to Basics for Medical Review Officers. Updated 2023.
• DNA Legal. A Guide to Ketamine Drug Testing. August 2021.
• HCPLive. FDA Approves Esketamine as First Monotherapy for Treatment-Resistant Depression. January 2025.